Vibha Ravi
Senior Editor

Vibha provides news and analysis for Pink Sheet and Scrip on a broad range of subjects related to companies, including deals, strategy, regulation and policy. Her multimedia content including infographics and podcasts have helped her win internal awards. She brings her education in business management and experience as a senior journalist for AFX-Asia to bear in spotting trends. As an attendee and panelist at conferences, she strives to bring unique insights to the audience. In her spare time, she enjoys travel, photography and blogging.
Latest From Vibha Ravi
Is The US Less Attractive Than India? A Proxy Comparison Via Strides And Torrent
Scrip examines Torrent Pharma and Strides Pharma’s divergent strategies and Q4 financial performance in the US and India while presenting an infographic to compare market-wise metrics
Zydus Looks To NASH Trials In Turkey, Generic Vascepa Launch In The US
Zydus, the only Indian company with an NCE for a range of chronic liver diseases, will add Turkey to the list of trial locations for NASH. It is also working “aggressively” to launch a generic to Amarin’s Vascepa after Revlimid and Trokendi generics drove record US sales in the fourth quarter.
US Drug Shortages Aid Aurobindo’s Q4 Growth, Decentralized Trials On For Xolair Biosimilar
Drug shortages, stable prices and a demand recovery in the US helped drive Aurobindo’s growth in Q4. Meanwhile, the company is developing a biosimilar to Roche/Novartis’s multi-billion product Xolair, as predicted by Scrip earlier. Use of decentralized mode for its Phase III trials is a notable aspect
Zydus Looks To NASH Trials In Turkey, gVascepa Launch In The US
Zydus, the only Indian company with an NCE for a range of chronic liver diseases, will add Turkey to the list of trial locations for NASH. It is also working “aggressively” to launch a generic to Amarin’s Vascepa after Revlimid and Trokendi generics drove record US sales in the fourth quarter
FDA’s Califf Speaks Of Tailoring Trials For CMS Evidence Amid Spotlight On Alzheimer’s Drugs
FDA Commissioner Robert Califf spoke of the need for a better hand-off to CMS, including tailoring trials to generate evidence relevant for Medicare coverage. He also weighed in on the possibility of accelerated approval for chronic disease drugs, among other topics.
Lupin's Generic Spiriva Launch Delayed As FDA Action Expected By August
Lupin has pushed the US launch for a generic to Boehringer’s blockbuster COPD drug Spiriva to September as FDA action is now expected “latest by August”. Meanwhile, an acquisition of Medisol in France and ANDA submissions in the US are part of an ongoing focus on injectables.